A PHASE 1 OPEN-LABEL DOSE FINDING STUDY OF CC-95251 A MONOCLONAL ANTIBODY DIRECTED AGAINST SIRPa ALONE AND IN COMBINATION WITH CETUXIMAB OR RITUXIMAB IN SUBJECTS WITH ADVANCED SOLID AND HEMATOLOGIC CANCERS

Brief description of study

The purpose of the study is to look at how your body tolerates CC-95251 and safety of the CC-95251 when administered intravenously (IV) as single dose and after multiple doses over the course of the study, when CC-95251 is taken alone, or in combination with cetuximab or rituximab. CC-95251 is an injectable intravenous (IV) treatment for solid tumors and hematological malignancies and will be administered as a single agent or in combination with effector-competent tumor targeting antibodies The study drug CC-95251 is investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.


Clinical Study Identifier: s19-01262
ClinicalTrials.gov Identifier: NCT03783403
Principal Investigator: Catherine M Diefenbach.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.